Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $29 | $23 | $17 | $13 |
| % Growth | 25.5% | 37% | 27.3% | – |
| Cost of Goods Sold | $10 | $3 | $16 | $14 |
| Gross Profit | $19 | $20 | $1 | -$1 |
| % Margin | 64.5% | 86.6% | 4.9% | -5.7% |
| R&D Expenses | $4 | $5 | $1 | $0 |
| G&A Expenses | $2 | $12 | $11 | $10 |
| SG&A Expenses | $20 | $15 | $14 | $12 |
| Sales & Mktg Exp. | $18 | $3 | $3 | $2 |
| Other Operating Expenses | $0 | $10 | -$2 | -$3 |
| Operating Expenses | $23 | $29 | $13 | $9 |
| Operating Income | -$5 | -$9 | -$12 | -$7 |
| % Margin | -15.4% | -38.4% | -69.6% | -49.2% |
| Other Income/Exp. Net | -$5 | $0 | -$5 | -$1 |
| Pre-Tax Income | -$9 | -$9 | -$17 | -$8 |
| Tax Expense | $0 | $0 | -$2 | -$1 |
| Net Income | -$9 | -$9 | -$15 | -$7 |
| % Margin | -31% | -37.7% | -89.8% | -56% |
| EPS | -0.037 | -0.043 | -0.096 | -0.051 |
| % Growth | 15.1% | 54.9% | -89.1% | – |
| EPS Diluted | -0.037 | -0.043 | -0.096 | -0.051 |
| Weighted Avg Shares Out | 247 | 204 | 160 | 149 |
| Weighted Avg Shares Out Dil | 247 | 204 | 160 | 149 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $3 | $2 | $2 |
| EBITDA | -$7 | -$6 | -$9 | -$8 |
| % Margin | -23% | -25.6% | -55.7% | -59% |